Gilead Sciences (Foster City, CA) Submits New Drug Application To U.S. FDA For Ambrisentan For The Treatment Of Pulmonary Arterial Hypertension

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of ambrisentan (5 mg and 10 mg) for the once-daily treatment of pulmonary arterial hypertension (PAH). The application is supported by data from two Phase III clinical studies (ARIES-1 and ARIES-2) and three Phase II studies in patients with PAH.

Back to news